{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:04:01Z","timestamp":1795176241839,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1490-y","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T07:50:58Z","timestamp":1513929058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-1377","authenticated-orcid":false,"given":"Karel","family":"Pavelka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maradiaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Pricop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Readie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"issue":"9783","key":"1490_CR1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127\u201337.","journal-title":"Lancet"},{"issue":"5","key":"1490_CR2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.berh.2014.10.007","volume":"28","author":"N Garg","year":"2014","unstructured":"Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol. 2014;28(5):663\u201372.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9570","key":"1490_CR3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390.","journal-title":"Lancet"},{"issue":"6","key":"1490_CR4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1586\/14737167.2014.957679","volume":"14","author":"K Kotsis","year":"2014","unstructured":"Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):857\u201372.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1490_CR5","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"issue":"4","key":"1490_CR6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1490_CR7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1490_CR8","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D Heijde van der","year":"2009","unstructured":"van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis Jr JC. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68(6):922\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1490_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14728214.2015.993378","volume":"20","author":"J Braun","year":"2015","unstructured":"Braun J, Kiltz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs. 2015;20(1):1\u201314.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"9","key":"1490_CR10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11926-013-0356-9","volume":"15","author":"J Sieper","year":"2013","unstructured":"Sieper J. Treatment challenges in axial spondylarthritis and future directions. Curr Rheumatol Rep. 2013;15(9):356.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"1490_CR11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2133.2010.09950.x","volume":"163","author":"PPM L\u00fcmig Van","year":"2010","unstructured":"Van L\u00fcmig PPM, Lecluse LLA, Driessen RJB, Spuls PI, Boezeman JB, Van De Kerkhof PCM, De Jong EMGJ. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol. 2010;163(4):838\u201346.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1490_CR12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415\u201329.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1490_CR13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nrrheum.2016.7","volume":"12","author":"JH Duarte","year":"2016","unstructured":"Duarte JH. Spondyloarthropathies: IL-17A blockade ameliorates ankylosing spondylitis. Nat Rev Rheumatol. 2016;12(2):72.","journal-title":"Nat Rev Rheumatol"},{"issue":"9906","key":"1490_CR14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewe R, Wordsworth P, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705\u201313.","journal-title":"Lancet"},{"issue":"26","key":"1490_CR15","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"4","key":"1490_CR16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"9999","key":"1490_CR17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewe R, Conaghan PG, Gottlieb AB, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"14","key":"1490_CR18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewe R, Nash P, Pricop L, Yuan J, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"1490_CR19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73(2):349\u201356.","journal-title":"Ann Rheum Dis"},{"key":"1490_CR20","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"W Hueber","year":"2010","unstructured":"Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52ra72.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1490_CR21","first-page":"1226","volume":"15","author":"AB Gottlieb","year":"2016","unstructured":"Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial. J Drugs Dermatol. 2016;15(10):1226\u201334.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1490_CR22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.berh.2014.10.019","volume":"28","author":"F Bosch Van den","year":"2014","unstructured":"Van den Bosch F, Deodhar A. Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Pract Res Clin Rheumatol. 2014;28(5):819\u201327.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"Suppl 3","key":"1490_CR23","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1086\/430000","volume":"41","author":"SG Filler","year":"2005","unstructured":"Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis. 2005;41 Suppl 3:S208\u201312.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1490_CR24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","volume":"25","author":"R Perez-Alvarez","year":"2013","unstructured":"Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25(1):56\u201364.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"1490_CR25","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886\u201395.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1490_CR26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jbspin.2008.09.017","volume":"76","author":"S Ottaviani","year":"2009","unstructured":"Ottaviani S, Cerf-Payrastre I, Kemiche F, Pertuiset E. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis. Joint Bone Spine. 2009;76(3):312\u20133.","journal-title":"Joint Bone Spine"},{"key":"1490_CR27","unstructured":"HUMIRA: Highlights of prescribing information. [\nhttp:\/\/www.rxabbvie.com\/pdf\/humira.pdf\n\n]. Accessed 21 Nov 2016."},{"key":"1490_CR28","unstructured":"ENBREL: Highlights of prescribing information. [\nhttp:\/\/pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf\n\n]. Accessed 21 Nov 2016."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1490-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T07:51:14Z","timestamp":1513929074000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1490-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1490-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732345838.793550508","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"285"}}